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 Abstract
 Chagas disease, caused by  Trypanosoma cruzi infection, 
is ranked as the most serious parasitic disease in Latin 
America and has huge potential to become a worldwide 
problem, due to increasing migration, and international 
tourism, as well as infectant transfer by blood contact and 
transfusion, intrauterine transfer, and organ transplanta-
tion. Nearly 30 % of chronically-infected patients become 
symptomatic, often with a latency of 10 – 30 years, devel-
oping life-threatening complications. Of those, nearly 90 % 
develop Chagas heart disease, while the others manifest 
gastrointestinal disease and neuronal disorders. Besides 
interrupting the infection cycle and chemo therapeutic 
infectant elimination, starting therapy early in sympto-
matic patients is important for counteracting the disease. 
This would be essentially supported by optimized patient 
management, involving risk assessment, early diagnosis 
and monitoring of the disease and its treatment. From 
economic and logistic viewpoints, the tools of laboratory 
medicine should be especially able to guarantee this. After 
summarizing the basics of chronic Chagas disease, such as 
the epidemiological data, the pathogenetic mechanisms 
thought to drive symptomatic Chagas disease and also 
treatment options, we present tools of laboratory medicine 
that address patient diagnosis, risk assessment for becom-
ing symptomatic and guidance, focusing on autoantibody 
estimation for risk assessment and heart marker measure-
ment for patient guidance. In addition, increases in levels 
of inflammation and oxidative stress markers in chronic 
Chagas disease are discussed. 
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 Introduction 
 Chagas disease, caused by infection by the flagellate pro-
tozoan  Trypanosoma cruzi is the most serious parasitic 
disease in Latin America  [1] . The disease was named in 
honor of the Brazilian physician Carlos Chagas (born in 
1879 in Oliveira, died in 1934 in Rio de Janeiro) who dis-
covered  T. cruzi as the infecting agent in 1909. 
 Due to the establishment of life-threatening compli-
cations in nearly 30 % of infected subjects, manifesting in 
the majority as Chagas heart disease, a minority of patients 
develop gastrointestinal disorders. There are also patients 
who present with both complications. Chagas disease is cur-
rently the major cause of morbidity and mortality in Latin 
America, enormously burdening economic resources and 
dramatically affecting patients ’ social and labor situations. 
 International migration processes have brought 
infected subjects from Latin America to the rest of the 
world, so Chagas disease is increasingly becoming a 
worldwide problem for healthcare systems. Consequently, 
to counteract Chagas disease in general and specifically 
the development of the life-threatening complications, 
early diagnosis and risk assessment for becoming symp-
tomatic and optimal patient guidance are prerequisite. In 
this context, and from economic and logistic viewpoints, 
the tools of laboratory medicine should be able to guar-
antee this. In addition, prevention concepts and modern 
treatment strategies are also critical. 
 Here, the basics of chronic Chagas disease are sum-
marized, such as the epidemiological data, pathogenetic 
mechanisms thought to drive the disease and treatment 
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Chagas disease in endemic areas. Both the female and male 
triatomine bugs are able to transmit  T. cruzi throughout their 
lifetimes (up to 2 years). Further stages run in the blood and 
tissue of mammals (reservoir hosts). 
 Recently, the WHO  [1] listed more than 180 wild, 
domestic and peridomestic mammals which are important 
as reservoirs; among this group, marsupials, edentates 
and rodents, as well as pets and livestock are prominent. 
The infectious form of  T. cruzi , also called the metacyclic 
trypomastigote form, circulates freely after entering the 
host and, in this stage, is open for immunological attack. 
However, the vulnerability towards immunological attack 
diminishes after colonization of the trypomastigotes in 
phagocytic and non-phagocytic cells of the host ’ s tissues. 
The variety of cells which act as a reservoir for the parasite 
is large, although a clear tropism exists for muscular and 
neuronal cells. Of the muscle cells, those of the heart and 
skeleton, as well as smooth muscle cells are affected to a 
similar degree. After cell colonization, the trypomastigotes 
transform to amastigotes which are able to replicate. After 
re-transformation of amastigotes into infectious trypomas-
tigotes, and following cell lysis, trypomastigotes enter the 
blood circulation. From human blood, as well as from any 
other mammalian blood contaminated with the trypomas-
tigotes, the parasite can be taken up by the triatomine bug 
when it sucks blood. In the mid-gut of the bug, the try-
pomastigote transforms into the epimastigote form, which 
is better adapted for survival within the insect, meaning 
that it is again able to replicate. Epimastigotes re-transform 
in the hindgut of the bug into infectious trypomastigotes 
that are excreted with feces and enter humans and other 
mammals, thus continuing the vicious cycle of  T. cruzi 
infection. Infectious feces of the bugs pass via the bite or 
other small wounds into human blood, but the parasite 
can also pass from the feces through intact mucous mem-
branes, especially of the mouth and the eyes. The feces 
remain infectious for a long time, probably even when 
outside the bug. Consequently, infection via the ingestion 
of food contaminated with feces has been reported  [4] . 
 Due to triatomine bug cannibalism,  T. cruzi can also 
be spread among populations. In contrast, birds and rep-
tiles do not carry  T. cruzi. 
 The risk area of vectorial  T. cruzi transmission ranges 
from the south of the US to the north of Argentina. However, 
in the south of the US, only a very small number of vector-
borne cases of infection have been reported  [5] . Despite 
successful multinational initiatives for interrupting  T. cruzi 
transmission in Latin America, it was estimated that, there 
were still 28 million people at risk and 15 million infected 
cases in 2006, and an annual incidence and mortality of 
41,200 and 12,500 people, respectively  [6] . 
Infectants  T. cruzi 
[ T. cruzi I,  T. cruzi II (new typing:  T. cruzi I-VI)]
Vectors Triatomine bugs 
(Predominantly  Triatomina infectance, Rhodnius 
prolixus, Triatoma dimidiata )
Wild mammal 
reservoir 
hosts
More than 180 mammals predominantly: marsupi-
als (opossums), edentates (armadillos, sloths), 
 chiroptera (bats), rodents (mice, rats, squirrels, 
porcupines, beavers, guinea pigs, hamsters), but 
also apes, foxes, deer
Domestic and 
peridomestic 
mammal res-
ervoir hosts
Humans, dogs, goat, cattle, sheep, guinea pigs, 
cats, mice, rabbit, rats, pigs
Non-vector 
routes of  T. 
cruzi transfer
Blood transfusion, diaplacental transmission, 
oral transmission by mother milk, transmission 
by sexual contact (contact with menstrual blood, 
injury during sex), organ transplantation, contact 
with infected blood (accidental transmission), oral 
transmission of contaminated food
 T. cruzi dis-
persion
Emigration of infected subjects, infection during 
tourism, blood product trading
Victims Humans, dogs
 Table 1   Trypanosoma cruzi basic information. 
options. Furthermore, tools of laboratory medicine will 
be presented that address patient diagnosis, risk assess-
ment for becoming symptomatic and guidance, focusing 
on autoantibody estimation for risk assessment and heart 
marker measurement for patient guidance. In addition, 
increases in levels of inflammation and oxidative stress 
markers in chronic Chagas disease are discussed. 
 Basics of Chagas disease 
 Etiology and epidemiology 
 Trypanosoma  cruzi has been divided into two major line-
ages:  T. cruzi I and  T. cruzi II (with the latter also consisting 
of subgroups), which show differences in their regional dis-
tribution and pathogenic potency for cardiomyopathy and 
gastrointestinal diseases  [2] . Based on a recent consensus 
meeting, it was recommended that  T. cruzi strains should 
be referred to by six discrete typing units ( T. cruzi I-VI)  [3] . 
 Trypanosoma cruzi exists in three morphological forms, 
which demonstrate different life cycle phases. The life cycle 
of  T. cruzi involves stages in the digestive tract of triatomine 
bugs (secondary host) as the vector. As summarized in Table 
 1 , among Triatominae, the genera of  Triatoma infestans , 
 Rhodnius prolixus ,  Triatoma brasiliensis and  Panstron gylus 
megistus are of special importance for transmission of 
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 Outside the endemic area, it was estimated that there 
are more than 300,000 infected people in the US, based on 
the immigrant population of 23 million Latin Americans 
and the known prevalence of  T. cruzi -infected subjects in 
their countries of origin  [7] . In Australia and Canada, with 
85,000 and 157,000 immigrants, 3000 and 5000 people 
were estimated to be infected, respectively  [8] . 
 Europe is also not spared from Chagas disease  [9] , and 
it is increasingly being recognized as an emerging public 
health problem in European countries  [10, 11] . Based on 
a recently published epidemiological study with data col-
lection in nine European countries  [12, 13] , which clearly 
indicated the impossibility  “ to identify all people at risk 
due to the lack of data stratified by endemic countries ” , 
there are more than three million migrants from endemic 
countries living in Europe, mostly in Spain, with about 
1,750,000 subjects, followed by the UK and Italy. The 
estimated number of infected people was 68,318 – 123,078 
among the study population, which resulted in a preva-
lence of 2.0 % – 2.36 % . Clearly, the highest infection rate 
has been calculated for Spain, with 47,984 – 86,618 (preva-
lence 2.7 % – 4.9 % ) infected individuals. In the other Euro-
pean countries that were studied, the prevalence ranged 
between 0.4 % and 0.7 % in the Netherlands and 2 % – 4.8 % 
in Switzerland. However, in the remaining European 
countries the total number of infected individuals was 
much lower among European children adopted from 
endemic areas, with the prevalence of infection being 
calculated as 1.2 % – 2.4 % , indicating an infection rate of 
474 – 919 individuals. 
 There is presently no indication of vector-borne 
T. cruzi transfer in Europe. However, Europe is colonized 
by different subfamilies of the triatomine bug, includ-
ing species of the Triatominae subfamily. Among these, 
 T. rubrofasciata is known to be a  T. cruzi carrier in Latin 
America. However, as previously summarized  [14] , various 
species of flea, fly, bedbug, mosquito and lice have been 
suggested as possible candidates for  T. cruzi transmission. 
Ticks ( Ixodida ), were seen as another potential vector for 
 T. cruzi in Europe, as some tick subspecies can carry  T. 
cruzi , but it has not yet been demonstrated that ticks are 
able to transfer  T. cruzi to humans. Whether this situation 
will change in the existence of advancing climate shifts, 
as proposed for other infectious diseases, such as Dengue 
and Malaria, is presently still speculative  [15] . 
 Consequently, non-vector routes of  T. cruzi transmis-
sion are clearly more important outside of the endemic 
areas, as also in the endemic countries, due to the increas-
ing success of counteracting the vectorial  T. cruzi transmis-
sion. Among the non-vector routes, vertical transmission 
by intrauterine parasite transfer is the most important  [16] . 
 For Europe, after the documentation of one case of 
 T. cruzi transmission from a mother to child in Spain  [17] , 
a study was recently published stating that among 3839 
pregnant women who migrated from Latin America living 
in the area of Madrid, 3.96 % were found to be positive for 
 T. cruzi infection. Due to the high prevalence of  T. cruzi 
infection in the country of origin, up to 11.4 % of pregnant 
women who migrated from Bolivia were sero-positive 
for  T. cruzi infection. Four cases of congenital transmis-
sion (2.6 % ) were found, and all infected children were 
born to Bolivian mothers  [18] . Consequently, initiatives 
for the implementation of screening programs for preg-
nant women at risk of  T. cruzi infection have been sug-
gested  [19] . Congenital  T. cruzi transmission has also been 
detected in Switzerland  [20] , and all cases were again seen 
in children born to Bolivian mothers. 
 Trypanosoma cruzi transmission by infected mother ’ s 
milk or by milk contaminated with blood from papil-
lary fissures has been described as cited in  [21] but these 
appear to be rare events. The potential risk of  T. cruzi 
transmission by transplantation of infected organs should 
be not neglected  [22] . Transmission during sexual contact 
can also not be excluded. 
 Since unknown  T. cruzi carriers can serve as blood 
donors, about 100 million people are at risk of infection 
via contaminated blood  [23, 24] . Other groups at risk of 
 T. cruzi infection are occupational groups, such as social 
and healthcare employees who could come into contact 
with the blood of infected subjects. Consequently, blood 
donor screening began in 2007 in the USA  [25] . Since 2005, 
Spanish regulatory law  [26] has required that all at-risk 
donors (people born in an endemic area, people whose 
mothers were native to an endemic area and people who 
have undergone blood transfusions in an endemic area) 
are screened for Chagas disease and excluded from dona-
tion in the case of positivity. International tourism could 
increasingly become another route for the worldwide 
spread of Chagas disease as recently demonstrated by an 
Italian traveler  [27] . Altogether, the worsening problem 
concerning Chagas disease in Europe is now more fre-
quently seen in other countries  [10, 28, 29] . 
 From acute to chronic Chagas disease 
 After infection with  T. cruzi , based on some excellent 
reviews  [30 – 33] and illustrated in Figure  1  [34] , the acute 
stage of Chagas disease starts and lasts for some weeks 
or months. The acute stage can be symptomless or can 
present only mild clinical symptoms, such as fever, malaise 
and lymphadenopathy. The unspectacular presentation 
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of the acute Chagas stage is seen as a result of parasite 
control by humoral and cellular immune responses 
and their cytokine-signaled interactions, as extensively 
reviewed  [35 – 38] . However, their highly complex interac-
tions are far from being clarified. Hepatosplenomegaly, 
myocarditis, and meningoencephalitis are only occasion-
ally seen, and only in a small number of patients, espe-
cially children. The mortality rate due to acute Chagas 
disease is 2 % – 6 % , which is mainly through myocarditis 
and meningoencephalitis  [39, 40] . In contrast, it seems 
that a host ’ s defenses against  T. cruzi can decrease over 
time, or that immune suppression elements that come 
directly from  T. cruzi cause ineffective parasite control by 
the immune system. Both could contribute to incomplete 
parasite eradication, causing lifelong parasite persistence 
and resulting in chronically infected patients  [41] . Conse-
quently, the immune system in Chagas disease seems to 
clearly be a case of Dr. Jekyll and Mr. Hyde. 
 Due to the unspectacular acute stage, antiparasitic 
therapy is not often offered. Such therapy would clearly 
be helpful in the acute stage of the disease for parasite 
elimination. Without it, lifelong parasite persistence 
is maintained and the progression to chronic Chagas 
disease is favored. Fortunately, nearly 70 % of chronically 
infected subjects remain in a clinically asymptomatic 
stage throughout their lives. Unfortunately, the other 
30 % , frequently with a latency of decades, progress to 
symptomatic chronic Chagas disease, which is associated 
with the establishment of strong life-threatening compli-
cations in several cases. The heart is affected in nearly 
90 % of such cases, and these patients present cardio-
myopathy associated with arrhythmias, heart failure and, 
frequently, sudden death. The remaining symptomatic 
patients suffer from gastrointestinal disorders, mainly 
manifested as mega-syndromes  [42, 43] , or neuronal dis-
orders that are especially focused on the parasympathetic 
nervous system  [44 – 46] . Some patients suffer from more 
than one complication. 
 Genetic variability has been discussed as being 
responsible  [47] for whether patients remain asympto-
matic or develop heart disease, gastrointestinal disease or 
neuronal disorders, but this debate has not yet been con-
cluded  [48] . Associations were observed between distinct 
HLA alleles and an increased risk of developing chronic 
Chagas disease in some studies  [49, 50] , but others denied 
finding any such relationships  [51] . 
 Chagas heart disease 
 Chagas heart disease becomes manifest with a com-
parable frequency in both men and women, with no 
racial differences, and mainly starts between the ages 
of 30 and 50 years  [52] . From the clinical point of view, 
Human exposure to T. cruzi.
(vectorial, via transfusion, congenital,
oral via organ transplant, accidental)
No infection
<5%-10% of
symptomatic cases Death from myocarditis or
meningoencephallitis
Cure (lower proportion
of cases than for the
indeterminate form)
Antiparasitic drugChronic phase in
determinate form
Reactivation
Permanent
indeterminate form Cardiac DigestiveCardiodigestive
10-30 years laterChronic phase in
indeterminate form
Antiparasitic drug
Antiparasitic drug Acute Chagas infection
(asymptomatic or symptomatic)
Cure (20%-60%
of cases)
Cure (50%-80%
of cases)
Immunosuppression
 Figure 1   Natural history of Chagas disease in man. 
 From [34] with permission of Elsevier; license no. 2936990088001. 
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chronic myocarditis, thromboembolic events, sudden 
cardiac death and congestive heart failure are typical of 
advanced Chagas heart disease. However, about 30 % 
of Chagas heart patients die from sudden cardiac arrest 
without any characteristic signs of advanced Chagas heart 
disease having been seen beforehand. The often apically 
aneurysmatic Chagas heart is thought to be the cause of 
thrombus formation, which may lead to thromboembolic 
events in the brain and lungs, and is thought to be respon-
sible for the high rate of sudden death in Chagas heart 
disease. However, the main life-threatening complication 
of chronic Chagas disease is the continuous progression 
towards severe heart failure. Nearly 60 % of patients die 
due to cardiomyopathy. 
 From an anatomical point of view, Chagas cardiomyo-
pathy is characterized by progressive heart enlargement 
due to chamber dilatation. The walls and septum can 
become thickened, and can be combined with hypokine-
sia of the septum and the posterior wall. The histopatho-
logical features of the Chagas heart include typical signs 
of diffuse and patchy chronic myocarditis that are detected 
by nests of T-cells, varying numbers of B-cells and mac-
rophages, diffuse interstitial fibrosis and a disturbed mor-
phology of myocytes. The conduction system in the heart 
also shows alterations  [53 – 55] . The microscopic detection 
of parasites in a chronic chagasic heart is only success-
ful in 10 % – 20 % of the patients tested. However, modern 
molecular diagnostic techniques using DNA amplifica-
tion tests show the appearance of parasites in almost all 
patients with Chagas heart disease  [56, 57] . 
 In contrast, the severity of heart disease does not cor-
relate with the occurrence of parasite DNA. This clearly 
indicates that direct heart damage in relation to parasite 
load and inflammation is not the only mechanism that 
must be considered. It is assumed that both the parasite 
and the host exert an influence on the pathogenesis of 
Chagas heart disease  [58] . 
 Chagas gastrointestinal disease 
 The gastrointestinal manifestations of chronic Chagas 
disease are mainly seen as megaesophagus, megacolon, 
megastomach, megaduodenum, megajejunum, mega-
gallbladder and megacholedochus  [42, 43] . Malnutrition 
caused by swallowing problems and regurgitation leading 
to weight loss, as well as obstipation accompanied by 
abdominal pain, mark the progress of chronic Chagas 
disease to megaesophagus and megacolon. Manometric 
investigation can be used to indicate abnormalities in the 
esophagus motility even in asymptomatic patients  [43] . 
Symptomatic patients present with typical radiological 
signs. Radiological investigation employing barium as the 
contrast agent is the frequently used method for the diag-
nosis of megacolon. However, a simple radiological inves-
tigation is often sufficient. As in megaesophagus, mano-
metric investigation to indicate early stages of megacolon 
can be helpful  [43] . 
 The nervous system in chronic Chagas disease 
 Damage to the parasympathetic nervous system may be 
one of the primary events in the pathogenesis of symp-
tomatic Chagas disease and may contribute to heart and 
gastrointestinal Chagas disease in this way  [44, 45] . It is 
assumed that the damage to the parasympathetic nervous 
system starts in the acute phase and proceeds into the 
chronic phase. 
 As summarized previously  [59] , the central nervous 
system is mostly affected during the acute phase of the 
disease and predominantly presents with encephalitis. 
Fever, headache, vomiting and seizures are typical char-
acteristics. In chronic chagasic patients, the acute form 
can often be reactivated in cases of exogen- or endogen-
initiated immunosuppression. The chronic nervous form 
of Chagas disease is seen as a consequence of the lesions 
that are initiated in the acute or reactive state of Chagas 
disease, and can present with histopathological findings 
of mild inflammation signs. However, most of the chronic 
chagasic patients have no profound signs of neurologi-
cal alterations. Rare cases of changes in the psyche of 
 chronically-infected Chagas patients are also a sign of 
nerve damage during the chronic phase of the disease. 
 More important neurological issues are stroke 
 combined with brain atrophy and cognitive dysfunction 
following cerebral thromboembolic events in both asymp-
tomatic or cardiac-symptomatic Chagas patients. Even 
asymptomatic patients, but more prominently chronic 
chagasic heart patients, may present arrhythmias, apical 
aneurysm and mural thrombus, all of which correlate with 
embolic strokes  [60, 61] . A distinct number of patients with 
cerebral infarction secondary to Chagas disease present 
late vascular epilepsy as a complication. 
 Pathogenesis of symptomatic chronic 
Chagas disease with special focus on Chagas 
heart disease 
 Primary damage of the neuronal system, cell toxicity due to 
 T. cruzi and/or  T. cruzi -derived products, parasite-induced 
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microvascular alterations, polyclonal B-cell activation, 
triggering of T-cell-mediated responses induced by per-
sistent  T. cruzi antigens and autoimmunity induced by 
 T. cruzi -specific antigens or by the host antigen, have 
been proposed to drive the pathogenesis of symptomatic 
chronic Chagas disease  [33, 35, 62 – 64] . Although patho-
genic mechanisms have been analyzed with more detail in 
animal models and in patients with Chagas heart disease, 
which clearly mirror this disease ’ s predominance in 
symptomatic Chagas patients, much of the data found in 
Chagas heart disease can also be used to explain aspects 
of the gastrointestinal and neuronal manifestations. 
 A multiple background for the pathogenesis of Chagas 
heart disease can be not ignored. There is, on the one 
hand, now clearly demonstrated by modern techniques 
(e.g., PCR) a life-long persistence of  T. cruzi in the heart, 
which implicates more direct parasite-dependent damage 
mechanisms. This could be supported by immunological 
incompetence, among other mechanisms, importantly 
resulting from imbalances in regulatory T cells  [38] . Con-
sequently, reactivation of the parasite has been seen espe-
cially in HIV patients and also after transplantation  [65, 
66] . However, on the other hand, autoimmunity based 
on molecular mimicry and bystander activation has been 
increasingly seen as an important driver in the patho-
genesis of symptomatic chronic Chagas disease  [63] . It is 
known that  T. cruzi proteins cross-react with proteins of 
the host ’ s organs, which are then recognized by the host ’ s 
activated immune system  [63, 67] . However, the exact 
underlying mechanisms are far from being clarified. 
 Animal experiments focused on heart pathology  [68] 
have clearly indicated that immunization with  T. cruzi 
antigens, as well as the transfer of  T. cruzi -activated T 
cells, causes myocardial alterations, mainly focal myo-
carditis, demyelination and conduction system defects. 
Antigens, T cell clones and autoantibodies (AABs) found 
after infection with  T. cruzi persist for a long time, which 
supports the autoimmunity theory of symptomatic 
chronic Chagas disease. In the context of autoimmunity, 
so-called functional AABs directed to G-protein-coupled 
receptors (GPCRs), such as AABs against the  β 1-adrenergic 
( β 1-AABs),  β 2-adrenergic ( β 2-AABs) and muscarinergic2-
receptor (M2-AABs), were found in chronic chagasic 
patients and became increasingly important  [68] . In one 
of our own studies, almost 100 % positivity was found for 
both  β 1-AABs and M2-AABs, and 90 % positivity for  β 2-
AABs in Chagas heart patients. Patients with gastrointesti-
nal Chagas disease manifested with megacolon presented 
with nearly 100 % positivity for  β 2- and M2-AABs. Only 
38 % of the megacolon patients were positive for  β 1-AABs, 
and nearly 100 % of the patients who suffered both from 
chagasic heart and gastrointestinal disease were positive 
for all three AABs. In addition, positivity was also found 
for  β 1-AABs,  β 2-AABs, and M2-AABs in one third of all 
asymptomatic patients  [70] . All three of these antibodies 
are agonistic. Depending on different downstream effects, 
e.g., the activation of adenylate cyclase by  β 1-AABs and 
 β 2-AABs, and its inhibition by M2-AABs, positive or nega-
tive chronotropy are evident. In contrast to the physiologi-
cal receptor agonists, typical defense mechanisms in the 
presence of agonist overload, such as receptor down-reg-
ulation, was missed for the functional AABs. 
 G-protein-coupled receptors as autoantigens 
 Originally demonstrated for  β 1-AABs, but now also for 
M2-AABs and recently summarized  [69, 71, 72] , it is now 
well accepted that such autoantibodies are pathogenic 
substrates of cardiomyopathies and consequently also 
of Chagas heart disease. Among the underlying mecha-
nisms which are activated by  β 1-AABs and are heart-
pathogenic, are changes in action potential duration, 
altered Ca- and cAMP-dependent signal transduction 
associated with chronotropy and inotropy, and the stimu-
lation of apoptosis. These mechanisms result in cardio-
myopathy typical alterations, such as ultrastructural 
changes with focal myofibril lysis, the loss of normal 
myofilament banding patterns, the occurrence of hyper-
contraction bands, mitochondrial swelling and conden-
sation, sarcoplasmic vacuolation, and the deposition 
of dense granules in both sarcoplasm and myofibrils 
 [73] . For M2-AABs, decreased cAMP formation has been 
shown, whereas cGMP formation was increased, which 
supports a driving role of the parasympathetic nervous 
system. This could be responsible for the high incidence 
of atrial fibrillation in Chagas heart disease. In the gas-
trointestinal tract, M2-AABs inhibiting the parasympa-
thetic nervous system were postulated to be responsible 
for reduced motility. 
 Therapy 
 Therapy in the acute stage, during reactivated infection 
and after congenital infection concentrates on the elimi-
nation of the parasites, preferably by using Nifurtimox or 
Benznidazol  [34, 74 – 76] . While Nifurtimox has to be taken 
for between 50 and 120 days, Benznidazol is adminis-
trated for up to 60 days and, due to its safety and efficacy 
profile, is the first-line treatment option. 
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 However, some  T. cruzi strains can develop resistance 
against these drugs, with only 50 % of treated patients 
being drug responders. Furthermore, the existing drugs 
show enormous potential for toxic side effects, which 
manifest in the liver and as an allergic reaction, mainly 
after long-term administration. 
 The whole-genome sequencing of  T. cruzi in 2005 
revealed kinomes, which are known to contain a large 
and diverse set of protein kinases and phosphatases, and 
which could be used as targets in the future development 
of new, highly specific anti- T. cruzi drugs  [77] . 
 Anti- T. cruzi treatment can be offered to children and 
adults who do not have advanced Chagas heart disease, 
but it is contraindicated in pregnant women and subjects 
who suffer from kidney and liver insufficiency. 
 Due to the persistence of the PCR-detected myocar-
dial parasite, its suggested role in the pathogenesis of 
chronic symptomatic Chagas disease, and animal experi-
ments demonstrating the prevention of cardiomyopathy 
development following parasite reduction, a benefit of 
anti- T. cruzi treatment in the transition from the asymp-
tomatic stage to the cardiomyopathic stage and further 
to severe cardiomyopathy was supposed but still remains 
to be found.  “ BENEFIT ” , which is an under-study multi-
center trial on 3000 Latin Americans with mild to mod-
erate Chagas heart disease, could clarify the relation-
ship between trypanosomiasis interruption and cardiac 
disease progression and death  [78] . 
 After the manifestation of symptomatic Chagas 
disease, therapeutic possibilities are available that, in 
general, do not differ much from the treatment of cardio-
myopathies  [79, 80] and mega-syndromes of the gastroin-
testinal tract  [43] of other etiologies. 
 With respect to the Chagas heart disease, drug treat-
ment of heart failure, arrhythmias and thromboembolism, 
as well as pacemaker and cardioverter-defibrillator implan-
tation and resynchronization therapy are clearly indicated. 
 Although  β -blocker treatment in chronic Chagas car-
diomyopathy has been critically viewed due to bradyar-
rhythmia and conduction defects, there is now evidence 
of its beneficial effects in Chagas cardiomyopathy patients 
 [81, 82] . After the establishment of a cardioembolic risk 
score for chagasic patients, anticoagulation was recom-
mended, in particular for cardioembolic stroke prophy-
laxis  [83] . 
 Irrespective of the continuous optimization of drug 
therapy, the outcome of chronic Chagas patients with 
severe heart failure is very poor, which is similar to the 
outcome seen for patients with heart failure due to other 
etiologies. One-year survival rates from 20 % to 70 % were 
documented  [84, 85] . 
 Heart transplantation  [86] and assist device treatment 
for bridging until heart transplantation occurs, as well 
as destination therapy or bridging to recovery, are other 
options that have been tested  [87] . As is the case for cardio-
myopathy in general, cell-based therapy is being increas-
ingly discussed for Chagas cardiomyopathy  [88, 89] . 
 Considering the increasing acceptance of an autoim-
mune background in the pathogenesis of symptomatic 
Chagas disease, new treatment regimens directed to the 
removal or specific inhibition of AABs, which are similar 
to those used in other diseases with autoimmune back-
ground, could become increasingly important. In this 
context, the elimination of pathogenetic AABs, such as 
the pathogenic  β 1-AABs, via apheresis techniques has 
been suggested for Chagas heart disease  [90] . The idea of 
using apheresis in the treatment of Chagas heart disease 
is supported by the well-documented benefits of  β -1-AAB 
immunoadsorption in patients with DCM  [91] . 
 Last but not least  [92 – 95] , we recently reported results 
for the introduction of aptamers (for information about 
aptamers see  [96] ) as binders in the apheresis technique 
in order to clear plasma from the  β -1-AABs found in Chagas 
heart patients. In addition, aptamers could also be suit-
able for the in vivo neutralization of  β 1-AABs. This could 
offer a new strategy for the future treatment of patients 
with Chagas heart disease based on basics and a vision of 
aptamers future in cardiomyopathy treatment  [97] . 
 Laboratory medicine in Chagas 
disease 
 The detection of  T. cruzi and/or anti- T. cruzi antibod-
ies together with the use of conventional inflammation 
markers to diagnose Chagas disease and to guide asymp-
tomatic patients is the unique job of laboratory medicine. 
In contrast, a black box for physicians is the assessment 
of the patient ’ s risk of becoming symptomatic. No tools in 
cardiology, gastroenterology or neurology, or in labora-
tory medicine, can significantly assess this risk. For the 
early diagnosis of symptomatic Chagas disease, and guid-
ance of these patients, the highly sophisticated methods 
as commonly applied in heart, gastrointestinal and neu-
ronal diseases of other etiologies, are presently the first-
line option. However, such methods are cost and labor 
intensive, depend on highly qualified staff, and are only 
available in special centers in endemic areas which are 
often, far from patients ’ homes. Therefore, these centers 
have important economic and logistical problems that 
are particularly relevant to their common use in endemic 
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areas of Chagas disease. However, it is accepted that such 
problems could be of minor importance in developed 
countries. In contrast, laboratory medicine enables sam-
pling to be performed where patients are situated and 
also enables the subsequent economic investigation of 
samples at highly specialized and automated centers that 
guarantee the highest quality service. 
 Consequently, tools of laboratory medicine should 
be tested for their use in monitoring the asymptomatic 
Chagas stage, but mainly in the risk assessment of asymp-
tomatic patients, as well as their use in the diagnosis and 
monitoring of symptomatic Chagas disease. 
 Parasite detection and anti-T. cruzi antibody 
test for diagnosis 
 Trypanosoma cruzi in the circulating blood, especially at 
a high parasite titer which is predominantly observed in 
acute Chagas disease, can be directly detected by micro-
scopic examinations of thick or thin blood films stained 
with Giemsa. Xenodiagnosis and hemoculture are classic 
indirect methods. During the chronic stage, because of 
the low blood parasite titer, direct and indirect parasite 
detection is more difficult and parasite enrichment using 
the Strout method or microhematocrit can be sometimes 
helpful in these cases. 
 Alternatively, PCR-based detection of parasitic DNA 
in blood and tissue samples can be performed  [98, 99] . 
The PCR methods currently used are research tools and 
based on in-house developments. The methods are 
highly variable in their performance and are, in general, 
not supervised by a quality control system that is typi-
cally required in laboratory medicine. To bring the PCR 
detection of  T. cruzi DNA nearer to laboratory medicine, a 
multi-center study has recently been conducted  [100] . In 
this study, conventional and real-time PCRs were evalu-
ated with respect to a pre-defined  “ Good Performing 
Method ” using different  T. cruzi DNA control materials 
( T. cruzi DNA in bi-distilled water, seronegative blood 
spiked with cultured  T. cruzi and seropositive blood). 
Among the 48 tested PCRs, four of them were selected as 
being superior in their performance. However, as sum-
marized from a systematic analysis of the literature, and 
in contrast to former recommendations of PCR use for 
immunoassay confirmation,  “ currently, PCR should not 
be used in clinical practice for chronic Chagas disease 
diagnostics and there is no PCR test commercially avail-
able for this purpose ”  [101] . Regardless of this, in-house 
PCR, if well-standardized and controlled, as well as per-
formed by highly-qualified staff, is already an invaluable 
tool in Chagas parasite detection in our view, and will be 
even more so in the future. 
 During the acute phase of Chagas disease, anti- 
T. cruzi antibodies of the IgM type can be detected  [39, 102] . 
Chronic Chagas disease is most frequently diagnosed by 
the detection of IgG-type anti- T. cruzi antibodies, mainly 
by using ELISA, indirect hemagglutination, and indirect 
immunofluorescence. Initiated by the WHO  [103] , fre-
quently used assays for the detection of anti- T. cruzi anti-
bodies of the IgG type in chronic Chagas patients were 
compared in a multicentric study to assess the sensitivity 
and specificity of the assay. It was found that  T. cruzi anti-
bodies of the IgG type were detectable in hemagglutination 
assays (sensitivity = 88 % – 99 % , specificity = 96 % – 100 % ), 
particle agglutination assays (97 % – 100 % , 97 % – 99.5 % ), 
and ELISA (94 % – 100 % , 96 % – 100 % ). Indirect immuno-
fluorescence (sensitivity 98 % , specificity 98 % ), Western 
blot (100 % , 100 % ), immunoblot (98 % , 99.5 % ), and radio-
immunoprecipitation (100 % , 100 % ) confirmed the afore-
mentioned results. Based on the data collected in this 
study, the authors summarized that some of the ELISA 
results showed excellent sensitivities and specificities 
and could be used for screening donated blood and blood 
products. In contrast, hemagglutination assays were not 
recommended for  T. cruzi antibody detection, specifically 
for blood donor screening. WHO experts  [1] , and then later 
the FDA issued guidance entitled,  “ Use of serological tests 
to reduce the risk of transmission of  Trypanosoma cruzi 
infection in whole blood and blood components intended 
for transfusion ”  [104] recommended one-time blood testing 
for  T. cruzi antibodies with a licensed immunoassay test. 
Presently, two tests are licensed by the FDA and possess 
EC marking for application in Europe: the Ortho  T. cruzi 
ELISA Test System and the ABBOTT PRISM Chagas ChLIA. 
However, the  “ FDA intends to reevaluate the recommen-
dation for one-time testing after reviewing the outcome 
of ongoing studies … ” which would be in agreement with 
more restrictive regulation in endemic countries, such as 
in Brazil, which require a second test of a different tech-
nique for Chagas confirmation in blood donors who tested 
positively for  T. cruzi antibodies with an immunoassay. In 
addition, for epidemiological surveys, the use of one test 
has been recommended, which in our view, although not 
explicitly stated, should be ELISA. For diagnosis, patient 
guidance, and the detection of transplacental and peri-
natal transmission, two different tests are recommended 
of which one should be PCR. This procedure should also 
concern the detection of transplantation-associated trans-
mission, in our view. 
 With respect to cost, performance, and automation, 
immunoassays for anti- T. cruzi antibodies of the IgG type 
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are presently seen as first-line tools in the diagnosis and 
guidance of chronic Chagas disease, although there is a 
co-existence of  T. cruzi infected patients and those infected 
with Leishmaniasis parasites, as well as those who are 
carriers of the non-human pathogen  Trypanosoma rangeli 
in endemic Chagas areas. Parasite-specific IgGs of these 
groups of subjects can cross-react with anti- T-cruzi IgGs 
in the immunoassays producing false-positive results. To 
overcome this problem, immunoassays based on recom-
binant antigens were developed. Indirect immunofluore-
cence is currently still the most frequently used test for the 
confirmation of ELISA results. 
 Indirect immunofluorescence has a sensitivity that 
is close to 99 % but shows several disadvantages, such as 
the need for highly qualified and specialized technicians, 
limited sample throughput, problems in standardization 
and quality control and a low automation grade. After 
more and more overcoming of the start-up problems of 
PCR in diagnose or confirmation of the  T. cruzi infection, 
this method could become the future first-line tool. 
 Assessment of the asymptomatic Chagas 
patient ’ s risk of becoming symptomatic 
 A patient ’ s genetic disposition and the genetic diversity 
of  T .  cruzi could potentially determine risk  [105] , but a 
heterogeneous picture exists for genetic predisposi-
tion so far. At the HLA level, HLA-DBR1-1503 has been 
reported to be found more often in Chagas cardiomyopa-
thy patients compared to healthy controls  [106] . In other 
studies, genetic polymorphisms have been most fre-
quently studied, looking at proteins which are involved 
in the regulation of the inflammatory processes, as they 
accompany chronic Chagas disease  [107 – 110] . All of the 
identified polymorphisms correlate to a certain extent 
with the occurrence of Chagas heart disease without 
showing exclusivity. For the future, it remains to be seen 
whether the combination of several distinct polymor-
phisms might increase the predictive value for cardio-
myopathy risk. The same will be true for the increasing 
knowledge of the complex network of immunity, as well 
as for the identification of more myocardial genes that 
are specifically expressed in the chagasic heart  [111] . 
All of these could possibly be utilized to develop labo-
ratory medicine tools that can be used for risk assess-
ment and/or the early diagnosis of Chagas heart disease. 
Modern platforms, such as mass spectrometric profiling 
of serum, have been used increasingly for the identifica-
tion of novel serum markers in Chagas patients  [112, 113] . 
Finding such markers in asymptomatic patients and the 
evaluation of their potential for risk assessment would 
be a future step. 
 A more current and hopeful strategy for risk assess-
ment could, in our view, be based on screening for AABs 
in asymptomatic Chagas patients. Although AABs are seen 
as more general pathogenic drivers and are found in dif-
ferent pathologies  [69] , the detection of the AABs in indi-
viduals diagnosed as being  T. cruzi -infected but asymp-
tomatic patients could indicate their risk of developing 
Chagas heart and gastrointestinal disease. Recent findings 
of our group, suggest that nearly 30 % of asymptomatic 
Chagas patients are AAB-positive, which clearly parallels 
the epidemiological data on the incidence of symptomatic 
Chagas disease in chronically infected patients, and could 
support such a risk assessment strategy, given it will prove 
to be a truly prognostic value. The first preliminary data 
was recently presented, which showed that the finding of 
AABs in asymptomatic patients could predict their risk 
of becoming symptomatic  [114] . The use of the AABs, in 
particular M2-AABs, for risk assessment is also seen as a 
promising strategy by others  [115] . However, in order to 
verify the strategy of AAB screening for risk assessment 
in asymptomatic Chagas patients, prospective studies 
enrolling broad cohorts are indispensable. At the present 
time, to the best of our knowledge, no other AABs found 
in Chagas patients have been tested for risk assessment. 
 A bioassay has mostly been used for measuring AABs 
 [70] . In this assay, cultured neonatal rat cardiomyocytes 
are used as the substrate for AABs. The AABs are quanti-
fied by monitoring the chronotropic effects induced by the 
AAB-containing IgG fractions prepared from the patient ’ s 
blood. The addition of specific antagonists enables a dif-
ferentiation between  β 1-,  β 2-, and M2-AABs. The beating 
frequency measured in this bioassay, as an integral 
parameter of cell functionality, is an advantage as it cor-
responds to the concentration of AABs. Moreover, the bio-
assay also tests  β 1-AABs,  β 2-AABs and M2-AABs simulta-
neously. However, the limitations of this bioassay include 
sophisticated assay standardization, a lack of adequate 
control materials and extensive turnaround times. 
 There are other cell-based AAB quantification 
methods that can be used, with one example being the 
quantification of  β 1-AAB via cAMP formation in cultured 
cells that were engineered to express the recombinant 
receptor protein for  β 1-AABs. The quantification of cAMP 
was then possible using RIA or ELISA technology. Quanti-
fying the formation of cAMP using FRET technology might 
become important in the future  [116] . 
 Considering the time, cost and capacity of cell-based 
assays, the development of less costly but more practi-
cal, well-standardized and more universally available 
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immmunoassays seems to be an essential prerequisite 
for AAB measurement. For AAB quantification, both 
ELISA and RIA tests exclusively use AAB binding to small 
peptides that are homologous to extracellular receptor 
epitopes recognized by the AABs. However, immunoas-
says do not differentiate between functionally active and 
inactive AABs, which might be one of the reasons for the 
discrepancies in the results between ELISA tests and the 
bioassays which use AAB functionality for quantification 
 [117] . Nevertheless, ELISAs that were specific for  β 1-AABs, 
 β 2-AABs and M2-AABs have been frequently used in differ-
ent studies  [118, 119] . However, to the best of our knowl-
edge, no immunoassay for Chagas disease relevant AABs 
against GPCR has been standardized according to the 
requirements of laboratory medicine and is commercially 
available at present. 
 To establish a new method for the AAB measurement, 
our selected aptamers  [92, 95] could be potentially used as 
AAB binder in respective assays. 
 Patient monitoring in acute and chronic 
Chagas disease 
 For patient guidance in acute and chronic Chagas 
disease, and for monitoring the progress of the disease 
from asymptomatic to symptomatic by means of labora-
tory medicine tools, markers derived from: 1) the parasite 
background of the disease ( T. cruzi products, anti- T. cruzi 
antibodies); 2) the autoimmunity-associated pathogenesis 
(AABs, as already discussed before); and 3) general path-
ways involved in the pathogenesis of symptomatic Chagas 
disease (inflammation, oxidative stress, organ specific 
functional and structural alteration), could be helpful. 
 In view of 1) Chagas disease progression, mainly from 
the asymptomatic stage to the stage of developing the life-
threatening complications, should involve the detection 
of the different stages in  T. cruzi activity (e.g., the reactiva-
tion of the parasite) as the first-line strategy. As already 
indicated before and tested in clinical studies  [120, 121] , 
besides monitoring the  T. cruzi antibody titer, the infect-
ant detection and quantification by PCR will be the pre-
ferred method. 
 Many of the markers of 3) mainly those derived from 
inflammation and oxidative stress are non-specific. With 
respect to the organ-specific manifestation of chronic 
Chagas disease, markers which specifically indicate heart, 
gastrointestinal and neuronal alterations in the chagasic 
patient should be preferred. Unfortunately, there are no 
markers which are already established or currently being 
studied that could specifically be used for the detection 
of gastrointestinal and neuronal alterations in chronic 
Chagas patients. 
 In contrast, highly-specific heart markers, such as 
cardiac troponins and brain natriuretic peptide, are well-
established laboratory medicine tools, which, in our view, 
could possess potential for the diagnosis and monitoring 
of patients with Chagas heart disease. 
 Non-specific markers 
 Regarding the impact of inflammatory processes on the 
pathogenesis of symptomatic Chagas disease, inflam-
mation markers that are well-established in laboratory 
medicine should be appropriate, especially for disease 
and treatment monitoring. Based on the multiple roles of 
inflammation in the pathogenesis of Chagas disease  [122] , 
an increasing number of markers among chemokines, 
chemokine receptors, tumor necrosis factor, interferon 
gamma, constituents of prostaglandin, leucotriene and 
nitric oxide metabolism, platelet-activating factor, growth 
factors, matrix metalloproteinases and vasoactive com-
pounds, such as Endothelin-1, could be potentially used 
for monitoring Chagas disease. Considering the tight con-
nection between inflammation and oxidative stress, the 
measurement of markers of oxidative stress might also 
be helpful. Many of these markers (only a selection was 
referenced for demonstration) need to be tested in studies 
comparing asymptomatic patients and patients with 
Chagas heart disease, the last group due to a high preva-
lence among symptomatic patients. 
 Inflammation markers 
 The typical signs of inflammatory processes and immune 
responses are obvious, especially during the acute stage 
after infection with  T. cruzi . Consequently, the measure-
ment of cytokines and acute phase proteins could poten-
tially be used to monitor acute Chagas disease in general 
and specifically during treatment  [123, 124] . 
 When acute phase proteins and the serological pro-
files of chagasic children were compared  [125] , only the 
early acute stage showed an increase in specific anti- T. 
cruzi IgM. The intermediate acute stage showed high 
levels of anti- T. cruzi IgM and/or anti-galactose anti-
bodies (anti-Gal, which has been suggested to be an 
additional marker of the acute phase), as well as high 
levels of  α 2 -macroglobulin and specific anti- T. cruzi IgG. 
Finally, in the late acute stage, the level of IgM decreased 
but  α 2 -macroglobulin, CRP, anti-Gal and IgG levels were 
still high. In addition, increased  α 2 -macroglobulin and 
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CRP levels were shown when healthy controls and acute 
 T .  cruzi -infected children were compared  [126] . 
 For cytokines, such as TNF- α , IL-2, IL-6, IL-8 and IL-12, 
and soluble receptors, such as sIL-2R, sCD8 and sCD4, 
Chagas disease-associated changes were reported, espe-
cially during the acute phase of infection  [127 – 130] . The 
increased concentration of IL-2R agrees with findings in a 
mouse model, which showed that the expression of IL-2R 
was increased during immune suppression in the acute 
phase of infection. 
 Inflammation markers, such as CRP, are also increased 
in chronic chagasic patients when compared to healthy 
subjects, especially in those suffering from Chagas heart 
disease at an advanced stage. However, quite often the 
values found did not exceed the CRP cut-off used to diag-
nose acute inflammation  [131] . 
 In one of our own studies  [132] , when analyzing 
healthy controls and patients suffering from asympto-
matic chronic Chagas disease or heart and gastrointesti-
nal diseases, the levels of CRP and IL-6 were significantly 
increased, mainly in the patient group suffering from 
heart disease. In this group, levels of both CRP and IL-6 
were found to be above the inflammation-specific cut-offs 
in 41 % and 71 % of the patients, respectively. Addition-
ally, CRP and IL-6 concentrations, and the percentage of 
patients with values above the cut-offs, increased with 
the severity of heart disease, which agrees with recently 
published data for CRP  [133] . However, a distinct number 
of patients were also found in the asymptomatic and gas-
trointestinal groups in this study who presented with CRP 
and IL-6 concentrations above the cut-offs. 
 Unfortunately, another study failed to demonstrate 
significant changes in the level of CRP in Chagas heart 
patients compared to healthy subjects and asymptomatic 
patients, although a more pronounced variability was 
found in the CRP values in symptomatic patients  [134] . 
A recent study  [135] comparing levels of CRP, which were 
measured using a highly sensitive assay in patients suf-
fering from either chronic Chagas heart disease or from 
heart disease of another origin, demonstrated a slight CRP 
increase in parallel with the severity of cardiomyopathy, 
but without group-specific differences in view of the car-
diomyopathy origin. It was suggested that patients with 
Chagas heart disease could be more affected by cytokine 
release than patients with idiopathic dilated cardiomyo-
pathy. Although this was reflected by IL-6 levels, the levels 
of TNF- α did not differ between the two groups of diseases. 
However, for both diseases, the markers were higher than 
in healthy subjects  [136] , and the level of IL-6 correlated 
with the outcome. For TNF- α , comparable values, which 
were clearly higher than those for healthy subjects, were 
found in asymptomatic patients and in those with Chagas 
heart disease presenting left ventricular ejection fraction 
(LVEF)  > 50 % . Patients with EVEF  < 50 % showed even 
higher values  [137] . 
 Recently, it was reported that the plasma levels of TNF 
superfamily ligands were increased in patients with func-
tional, but not arrhythmogenic, disturbances, and that 
these death receptor ligands may be potential markers 
of ventricular dysfunction in chronic Chagas heart 
disease  [138] . In addition to this, TNF- α levels related to 
the disease stage and differences in nitric oxide levels 
between healthy subjects and asymptomatic and symp-
tomatic patients were also seen  [139] . In contrast, dif-
ferences in the concentration of TNF- α between healthy 
subjects and patients with mild cardiomyopathy were 
not always evident, whereas differences between mild 
and severe diseases were substantiated  [140] . Patients 
who suffered from both HIV infection and Chagas disease 
presented with higher levels of TNF- α and IL-6 compared 
with patients with HIV infection only  [141] . 
 Ex vivo stimulation with recombinant  T. cruzi antigens 
of blood cells collected from Chagas patients was another 
approach tried for the differentiation of different disease 
stages  [142, 143] . In this study, it was shown that the pro-
duction of cytokines (mainly IFN- γ and TNF- α ) increased 
relative to the chronic Chagas disease severity, especially 
for CD8 + T lymphocytes. It has also been demonstrated 
that anti-parasite treatment in chronic chagasic patients 
decreased the number of  T. cruzi -specific IFN- γ secreting T 
cells, using ex vivo measurements  [144] . 
 Summarizing this section, the acute disease stage can 
be detected by profound changes in the pattern of acute 
phase proteins and cytokines, which could be of interest 
as laboratory medicine tools for patient guidance at this 
stage of disease. Unfortunately, the data for acute phase 
protein and cytokine measurements in chronic Chagas 
disease are inconsistent. Consequently, the impact of 
these markers as laboratory medicine tools for the guid-
ance of chronic Chagas patients is still restricted, espe-
cially for monitoring progression from the asymptomatic 
stage to the symptomatic stage. 
 Markers of oxidative stress 
 Oxidative stress has been defined as a metabolic condi-
tion that is characterized by imbalances in the equilib-
rium status of the pro- and anti-oxidant system in favor 
of pro-oxidant formation. In the case of pro-oxidant 
over production, these highly reactive molecules react 
with molecular structures in all major chemical classes 
found in living cells, realizing their toxic potential, and 
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ultimately leading to cell death. Oxidative stress occurs in 
many pathophysiological situations including: hypoxia, 
hyperoxia, ischemia, inflammation and intoxication. 
 With respect to Chagas disease, oxidative stress pro-
duced during inflammation  – as also seen in general  – is 
needed for the host-innate immune response to control 
T. cruzi proliferation and phagocytosis. In cases of high 
 T. cruzi titers and consequently overboarding inflamma-
tion, the excessive production of oxidative stress non-spe-
cifically damages various molecular and cellular struc-
tures leading to pathophysiological consequences. During 
oxidative stress in Chagas disease, a  T. cruzi defense 
mechanism is induced which favors parasite intraphago-
somal survival, escape to the cytosol and proliferation to 
increase virulence  [145] . 
 Mitochondrial damage in advanced Chagas heart 
disease, possibly resulting from hypoxic and ischemic 
conditions, has been suggested as a further source of 
excessive pro-oxidant generation  [146, 147] . There are 
also indications that anti-parasite drug therapy in Chagas 
patients promotes oxidative stress which can be dimini-
shed by antioxidant co-treatment  [148] . 
 Treatment with antioxidant compounds prevented 
mitochondrial alterations in the heart of chagasic animals 
and reduced their pro-oxidant production  [149] . There-
fore, it is not surprising that oxidative stress has also been 
discussed as a general pathogenetic factor in heart failure 
 [150] , and especially in Chagas heart disease  [151, 152] . 
Consequently, markers indicating increased oxidative 
stress  [153, 154] were measured to demonstrate the impact 
of oxidative stress on Chagas disease, and it was found 
that anti-oxidant treatment can reduce oxidative stress 
in chagasic patients  [155] . The first evidence of oxidative 
stress in Chagas disease came from animal experiments 
that indicated an increase in oxidative stress during the 
acute phase of  T. cruzi infection. Increased oxidative stress 
in serum, especially in the heart, became visible via an 
increase in lipid peroxidation and protein carboxylation 
products. In parallel, a compensatory increase in antioxi-
dant capacity was also observed. The acute infection was 
followed by a time of reduced oxidative stress. 
 However, the chronic stage of Chagas disease was 
again accompanied by increased oxidative stress along-
side a reduction in antioxidant defense  [156 – 159] . An 
increasing number of markers have been suggested as 
laboratory medicine tools for monitoring oxidative stress 
in humans. Among the oxidative stress markers  [153, 154] 
myeloperoxidase is one that is applicable as a labora-
tory medicine tool in human studies. Myeloperoxidase, 
which is localized in neutrophil granulocytes, monocytes 
and tissue macrophages, is the molecular producer of 
hypochlorite, which is needed for parasite phagocyto-
sis, but can be responsible for tissue damage when an 
excess is produced. In cases of the excessive stimulation 
of inflammatory cells, myeloperoxidase is released into 
the serum. In acute coronary syndrome and heart failure, 
the resulting serum levels of myeloperoxidase are of prog-
nostic value  [160] . Increased myeloperoxidase activity has 
also been observed in the serum of Chagas patients  [161] . 
We, in contrast, did not find significant differences in the 
myeloperoxidase levels when comparing healthy subjects, 
asymptomatic Chagas patients and patients with chronic 
Chagas heart disease  [162] . However, the greatest varia-
tion in the level of myeloperoxidase was seen in asymp-
tomatic patients. 
 Other markers that have been used in human studies 
are products of lipid peroxidation, protein oxidation 
and protein nitration. The measurement of antioxidant 
defense compounds, such as anti-oxidant enzymes and 
non-enzymatic antioxidant compounds has also been 
used to assess oxidative stress in Chagas disease patients. 
It was recently shown that, compared to healthy controls, 
patients with chronic Chagas heart disease (NYHA I and 
II) presented with increased levels of oxidative stress, as 
indicated by an increase in levels of malone dialdehyde 
in the plasma  [163] , which was supported by our own 
findings of increased malon dialdehyde levels in asymp-
tomatic Chagas patients and patients with heart disease 
 [162] . 
 The increased levels of oxidative stress correlated 
with mitochondrial dysfunction in Chagas patients  [163] . 
In addition, lower blood activities of antioxidant enzymes 
(total superoxide dismutase, manganese superoxide dis-
mutase and glutathione peroxidase) and a lower level of 
the non-enzymatic antioxidant glutathione have been 
found. A reduced antioxidant defense was also found in 
other studies  [164, 165] . A deficiency in selenium was also 
found in chronic Chagas patients, especially in those with 
progressed cardiomyopathy  [166] . Although selenium is 
essential for glutathione peroxidase, which is one of the 
main constituents of the antioxidant defense system, the 
activity of this enzyme did not decrease in the chagasic 
patients of this study. 
 Recently, the over-expression of oxidative stress pro-
teins has been indicated among  T. cruzi isolates from 
patients with acute Chagas disease, which could be used 
as biomarkers of the clinical course of this disease  [167, 
168] . 
 Summarizing this section, there are signs of oxida-
tive stress in chagasic patients which could be reduced 
by anti-oxidant treatments, and both can be monitored 
with laboratory medicine tools. However, the results are 
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inconsistent, which could result from the use of very dif-
ferent markers (different species of pro-oxidants, non-
enzymatic and enzymatic anti-oxidative compounds, 
and different end-products of oxidative damage), which, 
consequently, mirror very different parts of the oxidative 
stress phenomenon. Furthermore, oxidative stress markers 
underlie some pre-analytic factors which cannot be very 
well handled. Last but not least, well-defined performance 
and standardization of these tests are missing in general. 
 Heart-specific markers 
 Abnormalities found in electrocardiography (ECG) and/
or echocardiography can be early indications of Chagas 
heart disease. In line with the diagnostic options avail-
able in endemic areas, cardiac arrhythmia found by ECG 
examination is often the first indication of chagasic car-
diomyopathy in chronically-infected patients who, from 
an anamnestic and clinical viewpoint, are clearly thought 
to be in the asymptomatic stage  [169] . Of the typical ECG 
abnormalities in chronic Chagas heart disease  [170] , right 
bundle branch block, left anterior hemiblock, ventricular 
extrasystoles, sinus bradycardia, auricular fibrillation 
and complete atrioventricular block are the most fre-
quently found with increasing severity of the disease. For 
the evaluation of newly diagnosed patients with chronic 
Chagas disease based on  T. cruzi antibody positivity 
 [171] , it was recommended that patients should undergo 
a medical history interview, a physical examination, and 
a resting 12-lead ECG with a 30-second lead rhythm strip 
and annual repetition in the case of normality. After diag-
nosing Chagas heart disease, a comprehensive cardiac 
evaluation is necessary, which should include a Holter 
ECG examination, echocardiography  [172, 173] and exer-
cise testing to differentiate coronary disease. MRT is also 
useful and can improve the diagnosis and management of 
chronic Chagas disease  [174, 175] . 
 In the last decade, highly-specific and sensitive 
cardiac markers, such as brain natriuretic peptides (BNP, 
NT-proBNP) and cardiac troponins (cTnT, cTnI), have been 
introduced in laboratory medicine and have been tested 
with regards to their potency to supplement or substi-
tute the cardiologic diagnostics and monitoring of heart 
disease. Before the introduction of these highly-specific 
and sensitive cardiac markers, and despite very limited 
specificity, enzymes, such as AST, and later  α HBDH, total 
CK and CK-MB, were widely accepted as blood markers for 
diagnosing myocardial damage, and especially damage 
related to ischemia and necrosis. However, due primar-
ily to their insufficient sensitivity, these markers were 
not able to indicate myocardial alterations, such as focal 
inflammation and small disseminated necrosis in the cha-
gasic heart. In two studies that addressed the problems of 
sensitivity and specificity by analyzing markers in blood 
samples obtained from the coronary sinus, superior cava 
vein and pulmonary artery, enzyme release, mainly of 
isocitrate dehydrogenase and  α HBDH, was shown to be 
evident in Chagas heart patients  [176, 177] . 
 As in general for heart failure, markers indicating the 
progression of fibrosis and hypertrophy in the chagasic 
heart have been missed for a long time. However, typical 
changes in the enzymatic composition of the failing heart, 
e.g., shifts in the CK isoenzyme, are well-known  [178] , 
which could also be expected for the chagasic hyper-
trophic heart. However, to the best of our knowledge, 
no such data currently exists. Recently, a decrease in the 
level of the M-type CK protein was reported in the chagasic 
heart, as has also been found in cardiomyopathic hearts of 
other etiologies. This was combined with the loss of total 
CK activity in the heart, particularly in Chagas patients 
 [179] , but this shift in myocardial enzyme pattern is not 
expected to be mirrored in the blood, making it unusable 
for diagnostics. 
 To the best of our knowledge, no information cur-
rently exists concerning the presence of macroforms of 
heart enzymes (e.g., Macro-CK) in the serum of chronic 
chagasic heart patients that have also frequently been 
found in elderly and chronically diseased subjects, pref-
erentially with an autoimmune background  [180] , that 
would be easily detected by electrophoretic techniques. 
 The currently preferred cardiac markers, based on 
analytical sensitivity and specificity, are natriuretic pep-
tides for the detection of ventricular dysfunction and 
cardiac troponins to indicate ischemic-necrotic condi-
tions in the heart. As a consequence, natriuretic peptides, 
preferably the brain natriuretic peptide with its marker 
BNP and NT-proBNP, are widely used for the diagnosis 
and monitoring of heart failure  [181] . Therefore, it is not 
surprising that these markers are frequently analyzed in 
patients with Chagas heart disease. 
 The estimation of natriuretic peptides in Chagas 
disease patients began in 1994 with the measurement of 
the atrial natriuretic peptide in chagasic rats  [182] , fol-
lowed in 2002 by its measurement in patients at different 
stages of Chagas disease  [183] . In this study, the level of 
atrial natriuretic peptide in the blood clearly increased 
from asymptomatic to chronic heart-affected Chagas 
patients, with a further increase also reported at the 12 
month follow-up. 
 As for heart failure in general, the plasma level of brain 
natriuretic peptide is the preferentially used indicator for 
ventricular dysfunction associated with chronic Chagas 
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disease. In the first study to use this peptide as an indi-
cator in 2002  [184] , a cut-off was calculated that enabled 
chagasic patients to be screened for heart disorders via 
plasma BNP (cut-off of 60.7 pmol/L, sensitivity and posi-
tive predictive value of 80 % , specificity and negative pre-
dictive value of 97 % ). Following this study, a number of 
comparable studies were performed which clearly gave 
evidence that the plasma BNP level reflects the severity 
of Chagas heart disease  [185 – 191] . In patients with chronic 
Chagas disease, e.g., characterized by LVEF  < 40 % , the 
level of BNP was significantly higher than that in patients 
with LVEF  > 40 % . The last patient group was not signifi-
cantly different from the healthy controls  [186] , and the 
level of BNP was found to be negatively correlated with 
the LVEF. Based on a specific BNP cut-off, left ventricu-
lar dysfunction was detected with high sensitivity, speci-
ficity and negative predictive value in chronic chagasic 
patients. Recently, it was suggested that the combination 
of ECG and BNP is the best strategy for detecting left ven-
tricular dysfunction in chronic Chagas patients  [192] , and 
that this combination is superior compared to the con-
ventional strategy of ECG and chest X-ray. Regarding the 
economic and logistical situations in endemic areas, this 
laboratory medicine-based strategy was recommended as 
a first-line strategy for the recognition of LV dysfunction 
in Chagas disease. 
 A further finding regarding BNP in Chagas heart 
disease was that an increase in BNP is related to the 
6 min walking distance  [193] . However, no relationship 
was found with the level of BNP when the exercise capac-
ity of Chagas heart patients was analyzed  [194] . It was 
recently found that the level of BNP was correlated with 
diastolic dysfunction in chronic chagasic patients  [195, 196] . 
 Using end points, such as death and heart transplan-
tation, the level of BNP can be used to predict the outcome 
of Chagas patients  [192, 193] . Recently, the efficiency of 
BNP measurement in risk stratification was reported 
 [197] . In this study, the prognostic value of BNP for all-
cause mortality among older adults with Chagas disease 
was found to be comparable to that of an ECG. Also, for 
the marker NT-pro-BNP, higher serum values and cor-
relations with disease severity were shown in chagasic 
patients with heart disease  [198 – 200] , which is clearly in 
agreement with the results of our own study  [162] . In this 
study, Chagas patients suffering only from heart failure or 
from heart failure combined with a gastrointestinal dis-
order were found to have significantly higher NT-proBNP 
levels than healthy subjects, patients with asymptomatic 
chronic Chagas disease and those with only a chagasic 
gastrointestinal disorder. Regarding the severity of cha-
gasic heart disease, the level of NT-proBNP significantly 
increased from asymptomatic Chagas patients to patients 
with mild/moderate cardiomyopathy heart failure and 
again to patients with severe cardiomyopathy. In summary, 
clinical studies qualified brain natriuretic peptide meas-
urements for severity differentiation in chronic chagasic 
heart patients mainly to demonstrate the progress from 
mild to severe cardiomyopathy which clearly point to 
the potential of brain natriuretic peptide measurements 
for patient guidance. However, significant trends for the 
increase of brain natriuretic peptides have been demon-
strated when comparing the following patients: negative 
for Chagas disease vs. positive for Chagas disease without 
ECG and echocardiographic abnormalities, with typical 
ECG abnormalities but without echocardiographic abnor-
malities, and with typical echocardiographic indices for 
progressed cardiomyopathy, as well as if patients were 
separated due to normal diastolic function and dysfunc-
tion  [196] . This shows that the measurement of brain 
natriuretic peptide could have potential for diagnostics in 
the early stage of chronic Chagas heart disease. However, 
in our view, a more sophisticated interpretation of the 
brain natriuretic peptide measurement (e.g., the compari-
son of patient values with age and gender related refer-
ence values) could force this. 
 The cardiac troponins I and T (cTnI; cTnT) have 
become the cornerstones in modern laboratory medicine 
for the diagnosis, risk stratification and therapy moni-
toring of patients with acute coronary syndrome  [201] . 
However, there are numerous other physiological heart 
stressors, e.g., exercise  [202] , general pathologies affect-
ing the heart  [203] and cardiac diseases, such as stable 
angina, myocarditis, and heart failure  [204, 205] , all of 
which are accompanied by serum cardiac troponin values 
that are clearly different from those of healthy controls 
(although they may be below or near the established 
cut-off values for non-ST elevation infarction). 
 Many of the conditions associated with a mild cardiac 
troponin release and thought to be  “ non- or minimal-
necrotic ” in origin are associated with inflammation. 
This was recently shown for cardiac troponin release in 
runners  [206] . 
 Considering the focal inflammation and microle-
sions found in the chagasic heart, it was suggested that 
chronic Chagas patients with heart disease might present 
with increased levels of cardiac troponins in their blood. 
Only two previous studies and a single patient observa-
tion have analyzed cardiac troponin levels in Chagas heart 
disease  [207 – 209] , which unfortunately did not indicate a 
profound relationship between Chagas heart disease and 
cardiac troponin release, probably because of the insuf-
ficient sensitivity of the assays. However, the currently 
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available, highly-sensitive cardiac troponin assays have 
now overcome this limitation. Using the highly sensitive 
cTnT assay for comparison of healthy controls, asympto-
matic Chagas patients and patients with chagasic gastro-
intestinal disease, we found recently that chagasic heart 
patients present with increased cTnT concentrations in 
their blood, whereby the cTnT level raised from mild to 
severe cardiomyopathy  [132] . This indicates that cardiac 
troponins, when measured using highly-sensitive assays, 
can be used in the guidance of Chagas patients. 
 Last, but not least, we suggest combining the meas-
urement of brain natriuretic peptide in chronic Chagas 
patients with cardiac troponin measurements to improve 
the prediction of patients with heart disease among 
T. cruzi -infected subjects. However, this must be substan-
tiated in future studies. 
 Summarizing this section, there is clear evidence 
that BNP/NT-proBNP alone, and probably better still in 
combina tion with cardiac troponins, can indicate heart 
alterations in Chagas patients. In this case, the tools of 
laboratory medicine are presently, especially in the diag-
nostics of the earliest heart alteration in chagasic patients, 
inferior compared to those of cardiologic diagnostics, 
mainly when echocardiography and MRT are used. With 
respect to cost and logistics, which prefer the use of heart 
markers when screening chronic Chagas patients, they 
seem to be well suited to increasing the pre-test probabi-
lity of cardiologic diagnostics in chagasic patients. 
 Conclusions 
 Chagas disease, which is the most serious parasitic 
disease in Latin America, and which mainly manifests 
as Chagas heart disease, places an enormous burden on 
the economic resources of these countries and dramati-
cally affects the social and employment status of Chagas 
patients. Due to the increasing migration of infected 
patients, intrauterine transfer and transfer via organ 
transplantation, international tourism, parasite transfer 
by transfusion and blood contact, Chagas heart disease is 
starting to become a major worldwide problem. 
 In order to counteract Chagas disease in general and 
specifically symptomatic Chagas disease presenting as 
heart, gastrointestinal and neuronal diseases, Chagas 
disease must first be accepted outside the endemic area as 
an important health problem. Second, mainly outside the 
endemic area, the knowledge regarding the disease basics, 
including etiology, epidemiological aspects, pathogene-
sis, and treatment options, must be increased. These must 
be combined with the establishment of optimal strategies 
Screening or suspicion of chronic Chagas disease
Anti-T. cruzi lgG measurement
(+)
(+)
(+)
(-)
(-)
Measurement of β1-, β2-muscarinergic2-receptor
autoantibodies
Measurement of B-type natriuretic peptide, cardiac
troponin
Hemagglutination assay/ELISA
Chronic Chagas disease
2 years
1 year
Risk of chronic Chagas heart disease
hs Tn assay
BNP/NT-proBNp
assay
Chronic Chagas heart disease
Bioassay/ELISA
 Figure 2   Suggested algorithm for combining autoantibody measurements and the measurements of B-type natriuretic peptide and cardiac 
troponins in chronic Chagas disease patients for risk assessment, diagnostics and monitoring. 
From  [210] , with permission of Springer; license no. 2910760939167. 
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for the diagnosis of  T. cruzi- infected patients, the develop-
ment of programs to assess the patient ’ s risk of becom-
ing symptomatic, and if patients progress to symptomatic 
disease, for the early detection and monitoring of Chagas 
heart, gastrointestinal and neuronal disease. 
 In our view, such programs should include laboratory 
medicine tools, mainly as autoantibody measurements 
in asymptomatic Chagas patients for risk  assessment, 
and the measurement of cardiac markers, such as brain 
natriuretic peptide and cardiac troponins for the diagnosis 
and monitoring of patients developing heart disease. An 
algorithm combining the measurement of AABs, B-type 
natriuretic peptide and cardiac troponins to support the 
fight against chronic Chagas heart disease by improved 
risk assessment, diagnosis and monitoring was recently 
suggested in  [210] and is demonstrated here in Figure  2 . 
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